ABIOMED INC Form 4 May 07, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations

may continue.

See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Weber David M

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

(Check all applicable)

Chief Operating Officer

Issuer

ABIOMED INC [ABMD]

(Last) (First) (Middle)

3. Date of Earliest Transaction

10% Owner

C/O ABIOMED, INC., 22 CHERRY

05/05/2015

(Month/Day/Year)

X_ Officer (give title below)

Director

Other (specify

HILL DRIVE

(Street)

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

Applicable Line)

Filed(Month/Day/Year) _X_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

DANVERS, MA 01923

(City)	(State)	(Zip) Tab	le I - Non-	Derivative	Secu	rities Acquir	red, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securit or Dispos (Instr. 3, 4	ed of		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, \$.01 par value	05/05/2015		A	11,250 (<u>5</u>)	A	\$ 0	138,335	D	
Common Stock, \$.01 par value	05/06/2015		S <u>(6)</u>	605 <u>(6)</u>	D	\$ 72.3424 <u>(7)</u>	137,730	D	
Common Stock, \$.01 par value	05/06/2015		S <u>(6)</u>	800 (6)	D	\$ 74.2644 (8)	136,930	D	

Edgar Filing: ABIOMED INC - Form 4

Common

Stock, \$.01 par value

S(6)

S(6)

S(6)

S(6)

S(6)

S(75.685)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

De

(Ir

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisab Expiration Date (Month/Day/Year		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy) (1)	\$ 13.88					04/23/2008(2)	04/23/2017	Common Stock	30,000
Stock Option (right to buy) (1)	\$ 13.8					05/23/2009(2)	05/23/2018	Common Stock	0
Stock Option (right to buy) (3)	\$ 5.86					05/28/2010(2)	05/28/2019	Common Stock	0
Stock Options (right to buy) (3)	\$ 5.86					03/31/2010(2)	05/28/2019	Common Stock	0
Stock Option (right to buy) (3)	\$ 10.03					06/03/2011(2)	06/03/2020	Common Stock	0

Edgar Filing: ABIOMED INC - Form 4

Stock Option (right to buy) (3)	\$ 22.44	05/22/2013(2)	05/22/2022	Common Stock	0
Stock Option (Right to Buy) (3)	\$ 23.15	05/14/2014(2)	05/14/2023	Common Stock	0
Stock Option (Right to Buy) (3)	\$ 21.55	05/14/2015(4)	05/14/2024	Common Stock	0

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Weber David M C/O ABIOMED, INC. 22 CHERRY HILL DRIVE DANVERS, MA 01923

Chief Operating Officer

Signatures

/s/ Stephen C. McEvoy (by power of attorney)

05/07/2015

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2000 Stock Incentive Plan.
- (2) This option becomes exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
- (3) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
- (4) These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 14, 2014. One third of these restricted stock units vested on May 5, 2015 (into an equal number of shares of common stock) upon the issuer's achievement of a certain performance milestone with the remaining vesting on the first and second anniversary of the date of the grant.
- (6) Sale of common stock pursuant to reporting owner's 10b5-1 plan solely for payment of withholding tax liability associated with the vesting of performance-based awards of restricted stock units.
- This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$72.0800 (7) and \$72.5900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (8) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$74.0300 and \$74.7900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the

Reporting Owners 3

Edgar Filing: ABIOMED INC - Form 4

Commission staff, the Issuer, or a security holder of the Issuer.

This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$75.4100 (9) and \$75.9600. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.